Skip to Main Content

C pneumoniae causes pneumonia and bronchitis. The clinical presentation of pneumonia is that of an atypical pneumonia. The organism accounts for approximately 10% of community-acquired pneumonias, ranking second to mycoplasma as an agent of atypical pneumonia. A putative role in coronary artery disease has not held up to close scientific scrutiny.

Like C psittaci, strains of C pneumoniae are resistant to sulfonamides. Erythromycin or tetracycline, 500 mg orally four times a day for 10–14 days, appears to be effective therapy. Fluoroquinolones, such as levofloxacin (500 mg once daily for 7–14 days) or moxifloxacin (400 mg once daily for 7–14 days), are active in vitro against C pneumoniae and probably are effective. It is unclear if empiric coverage for atypical pathogens in hospitalized patients with community-acquired pneumonia provides a survival benefit or improves clinical outcome.

+
Fajardo  KA  et al. Pneumonia outbreak caused by Chlamydophila pneumoniae among US Air Force Academy cadets, Colorado, USA. Emerg Infect Dis. 2015 Jun;21(6):1049–51.
[PubMed: 25988545]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.